株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

全身性エリテマトーデス市場:治療(抗マラリア薬、非ステロイド抗炎症性薬、コルチコステロイド細胞毒性免疫抑制薬、生物製剤、小分子)、地域別の予測

Systemic Lupus Erythematosus Market: By Therapies (Antimalarial Drugs, Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids Cytotoxic & Immunosuppressive Drugs, Biologics, Small Molecules) & By Region - Forecast (2016-2021)

発行 IndustryARC 商品コード 422599
出版日 ページ情報 英文 136 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=113.53円で換算しております。
Back to Top
全身性エリテマトーデス市場:治療(抗マラリア薬、非ステロイド抗炎症性薬、コルチコステロイド細胞毒性免疫抑制薬、生物製剤、小分子)、地域別の予測 Systemic Lupus Erythematosus Market: By Therapies (Antimalarial Drugs, Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids Cytotoxic & Immunosuppressive Drugs, Biologics, Small Molecules) & By Region - Forecast (2016-2021)
出版日: 2016年09月22日 ページ情報: 英文 136 Pages
概要

当レポートでは、世界の全身性エリテマトーデス市場について調査し、市場の動向と戦略的分析、治療別、地域別動向、および市場に参入する主要企業のプロファイルなどをまとめています。

第1章 全身性エリテマトーデス市場:概要

第2章 エグゼクティブサマリー

第3章 市場環境

  • 市場シェア分析
  • 競合分析
  • 製品ベンチマーキング
  • エンドユーザープロファイリング
  • 上位5社の財務分析

第4章 市場の力

  • 促進因子
  • 阻害因子
  • 機会
  • 課題
  • ポーターズファイブフォース分析

第5章 戦略的分析

  • バリューチェン分析
  • 価格分析
  • 機会分析
  • 製品/市場ライフサイクル分析
  • 供給者と販売業者

第6章 治療別

  • 抗マラリア薬
  • 非ステロイド抗炎症性薬
  • コルチコステロイド細胞毒性・免疫抑制薬
  • 生物製剤
  • 小分子

第7章 地域別市場

  • 欧州
  • アジア太平洋地域
  • 北米
  • その他

第8章 エントロピー

  • 拡大
  • 技術的発展
  • 合併・買収、合弁
  • 供給 - 契約

第9章 企業プロファイル

第10章 付録

目次

Systemic lupus erythematosus, also commonly known as lupus, is an autoimmune disease which results in inflammation of tissues in the body with common symptoms like fever, fatigue, skin rashes, malaise, joint pain, and temporary loss of cognitive ability. Immune response is directed toward the body's own cells, resulting in acute or chronic inflammation. Symptoms of lupus are general and hence often mistaken with symptoms of other diseases. This results in unnoticed progression of disease in the body. The disease is more common in women and usually affects individuals in the age group of 25 to 45. Although the main cause of disease is unknown, it is linked to genetic and hormonal factors. Globally increasing awareness about lupus is expected to remain key growth driver during the period of study.

Geographically, North America dominates the systemic lupus erythematosus market driven by best in class infrastructure, easy access to healthcare, higher awareness about the disease amongst citizens as well as practitioners, and higher spending by the citizens towards healthcare expenditure. North America was followed by Europe and Asia-Pacific as second and third largest markets for systemic lupus erythematosus market. Asia Pacific is projected to have fastest growth, owing to rapidly developing medical infrastructure, increasing medical tourism, increased spending, and increasing awareness amongst population in developing nations such as China, and India in this region.

This report identifies the global systemic lupus erythematosus market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the market drivers, restraints, growth indicators, challenges, and other key aspects with respect to the systemic lupus erythematosus market.

This report segments the systemic lupus erythematosus market on the basis of therapies and regional market as follows:

Systemic Lupus Erythematosus Market research report is classified on the basis of therapies. Some of the major therapies covered in this report are as follows: Antimalarial Drugs, Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids Cytotoxic & Immunosuppressive Drugs, Biologics, Small Molecules

This report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region

This report identifies all the major companies operating in the systemic lupus erythematosus market. Some of the major companies' profiles in detail are as follows:

F. Hoffmann-la roche ltd

Glaxosmithkline plc (gsk)

Hadasit medical research services and development

Hansa medical ab

Harbor biosciences

Table of Contents

1. Systemic Lupus Erythematosus Market - Overview

2. Executive Summary

3. Systemic Lupus Erythematosus Market Landscape

  • 3.1. Market Share Analysis
  • 3.2. Comparative Analysis
  • 3.3. Product Benchmarking
  • 3.4. End User Profiling
  • 3.5. Top 5 Financials Analysis

4. Systemic Lupus Erythematosus Market- Forces

  • 4.1. Drivers
  • 4.2. Increasing awareness about SLE in emerging economies
  • 4.3. Restraints
  • 4.4. Opportunities
  • 4.5. Challenges
  • 4.6. Porter's Five Forces Analysis
    • 4.6.1. Bargaining Power of Suppliers
    • 4.6.2. Bargaining Power of Buyers
    • 4.6.3. Threat of New Entrants
    • 4.6.4. Threat of Substitutes
    • 4.6.5. Degree of Competition

5. Systemic Lupus Erythematosus Market- Strategic Analysis

  • 5.1. Value Chain Analysis
  • 5.2. Pricing Analysis
  • 5.3. Opportunities Analysis
  • 5.4. Product/Market Life Cycle Analysis
  • 5.5. Suppliers and Distributors

6. Systemic Lupus Erythematosus Market, By Therapies

  • 6.1. Antimalarial Drugs
  • 6.2. Non-Steroidal Anti-Inflammatory Drugs (Nsaids)
  • 6.3. Corticosteroids Cytotoxic & Immunosuppressive Drugs
  • 6.4. Biologics
  • 6.5. Small Molecules

7. Systemic Lupus Erythematosus Market, By Geography

  • 7.1. Europe
    • 7.1.1. Germany
    • 7.1.2. France
    • 7.1.3. Italy
    • 7.1.4. Spain
    • 7.1.5. Russia
    • 7.1.6. U.K.
    • 7.1.7. Rest of Europe
  • 7.2. Asia Pacific
    • 7.2.1. China
    • 7.2.2. India
    • 7.2.3. Japan
    • 7.2.4. South Korea
    • 7.2.5. Rest of Asia-Pacific
  • 7.3. North America
    • 7.3.1. U.S.
    • 7.3.2. Canada
    • 7.3.3. Mexico
  • 7.4. Rest of the World (RoW)
    • 7.4.1. Brazil
    • 7.4.2. Rest of RoW

8. Systemic Lupus Erythematosus Market - Entropy

  • 8.1. Expansion
  • 8.2. Technological Developments
  • 8.3. Merger & Acquisitions, and Joint Ventures
  • 8.4. Supply- Contract

9. Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)

  • 9.1. Anthera pharmaceuticals inc
  • 9.2. Biotest ag
  • 9.3. Biotica technology ltd.
  • 9.4. Cephalon
  • 9.5. Cornerstone therapeutics inc.
  • 9.6. Creabilis therapeutics s.r.l.
  • 9.7. Dynavax technologies
  • 9.8. Eli lilly
  • 9.9. F. Hoffmann-la roche ltd
  • 9.10. Glaxosmithkline plc (gsk)
  • 9.11. Hadasit medical research services and development
  • 9.12. Hansa medical ab
  • 9.13. Harbor biosciences

More than 40 Companies are profiled in this Research Report, Complete List available on Request*

"*Financials would be provided on a best efforts basis for private companies"

10. Appendix

  • 10.1. Abbreviations
  • 10.2. Sources
  • 10.3. Research Methodology
  • 10.4. Bibliography
  • 10.5. Compilation of Expert Insights
  • 10.6. Disclaimer
Back to Top